3,4-Methylenedioxy-N-methoxyamphetamine

MDMEO
Clinical data
Other namesMDMEO; MDMEOA; MDMeOA
Routes of
administration		Oral[1]
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • 1-(2H-1,3-benzodioxol-5-yl)-N-methoxypropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H15NO3
Molar mass209.245 g·mol−1
3D model (JSmol)
  • CC(NOC)Cc1ccc2OCOc2c1
  • InChI=1S/C11H15NO3/c1-8(12-13-2)5-9-3-4-10-11(6-9)15-7-14-10/h3-4,6,8,12H,5,7H2,1-2H3 Y
  • Key:MTIKJUJMCMDSGM-UHFFFAOYSA-N Y
  (verify)

3,4-Methylenedioxy-N-methoxyamphetamine (MDMEO, MDMEOA, or MDMeOA) is a drug and a substituted amphetamine.[1] It is also the N-methoxy analogue of MDA. MDMEO was first synthesized by Alexander Shulgin.[1] In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dose is listed as 180 mg.[1] MDMEO may be found as white crystals.[1] It produces few to no effects.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDMEO.[1]

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ a b c d e f g h Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.